, Volume 28, Supplement 1, pp 59–68 | Cite as

The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France

  • Xavier ColinEmail author
  • Antoine Lafuma
  • Dominique Costagliola
  • Jean-Marie Lang
  • Pascal Guillon
Original Research Article


Background: Highly active antiretroviral therapy (HAART) has greatly enhanced HIV management, lowering the risk of clinical disease progression and death by substantially improving HIV-induced immune deficiency. Lower CD4 cell counts have consistently been associated with higher direct costs of HIV patient care. The aim of this study was to analyze HIV costs of care in France at different levels of HIV-induced immune deficiency (as measured by the CD4 cell count) using recent data from treatmentexperienced patients.

Methods: This analysis used data from the French Hospital Database in HIV, containing data on approximately 50% of the French HIV population. Patients were included in the analysis if they had visited a participating centre from 2003 to 2005, had CD4 cell counts determined at least twice during the study period, and had been prescribed at least two nucleoside reverse transcriptase inhibitors, one non-nucleoside reverse transcriptase inhibitor and two protease inhibitors since their first consultation. Resources consumed were counted and aggregated according to the CD4 cell count level. Standard costs were applied.

Results: Periods with the lowest CD4 cell counts were associated with increased prescription rates of antiviral agents (other than anti-HIV agents), antiparasitic drugs and antimycobacterial agents. Antiretroviral treatments accounted for 80% of all medications prescribed during the study period. Hospitalization rates decreased with increasing CD4 cell counts, with 0.72 hospitalizations per patient-year for those with CD4 cell counts of 50 cells/mm3 or less compared with 0.05 per patient-year for patients with CD4 cell counts greater than 500 cells/mm3. There was a clear trend towards lower mean healthcare costs per patient-year with decreasing immune deficiency; from h34 286 to h12 361.

Conclusions: Our study showed an association between the degree of HIVinduced immune deficiency (measured by CD4 cell count) and the costs of managing HIV infection among highly pre-treated, HIV-infected individuals in France in the HAART era.


Clinical Disease Progression High Direct Cost PMSI Database French Hospital Database Hospitalization Unit Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to thank Johann Fichou from Inserm for his contributions. They also acknowledge Emily de Looze (medical writer, Gardiner-Caldwell Communications, Macclesfield, UK), for her editorial support. Finally, the authors wish to thank the investigators at the participating FHDH centres and the patients included in this analysis. This project was financially supported by Janssen-Cilag SAS, France.

XC and AL have received study funding from Jansen Cilag. PG has declared that this project was financially supported by Jansen Cilag SAS, France.


  1. 1.
    Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563–608PubMedCrossRefGoogle Scholar
  2. 2.
    Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 Recommendations of the International AIDS Society — USA panel. JAMA 2010; 304: 321–33PubMedCrossRefGoogle Scholar
  3. 3.
    Yéni P. Rapport du Groupe d’Experts 2010 sur la prise en charge médicale des patients infectées par le VIH, (version préliminaire) Recommandations du groupe d’expert. 2010. Available from URL: ( [Accessed 2010 Aug 25]Google Scholar
  4. 4.
    European AIDS Clinical Society (EACS). 2009 Guidelines for the Clinical Management and Treatment of HIV-infected adults in Europe; Version 5. November 2009 [online]. Available from URL: ( [Accessed 2010 Aug 25]Google Scholar
  5. 5.
    Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–60PubMedCrossRefGoogle Scholar
  6. 6.
    Walensky RP, Paltiel D, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11–19PubMedCrossRefGoogle Scholar
  7. 7.
    Lane HC. Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med 2010; 18: 2–6PubMedGoogle Scholar
  8. 8.
    Holkmann Olsen C, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319–30Google Scholar
  9. 9.
    Phillips AN, Lundgren JD. The CD4 lymphocyte count and risk of clinical progression: the T cell in HIV infection and disease. Curr Opin HIV AIDS 2006; 1: 43–9PubMedCrossRefGoogle Scholar
  10. 10.
    Monforte A, Abrams D, Pradier C, et al., Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143–53PubMedCrossRefGoogle Scholar
  11. 11.
    Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era [abstract 537]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver, USAGoogle Scholar
  12. 12.
    Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006; 42: 1011–13CrossRefGoogle Scholar
  13. 13.
    Levy A, Johnston K, Annemans L, et al. The impact of disease stage on direct medical costs of HIV management: a review of the international literature. PharmacoEconomics 2010; 28 Suppl. 1: 35–47PubMedCrossRefGoogle Scholar
  14. 14.
    Ghatnekar O, Gisslen M, Hjortsberg C, et al. Medical resource use and cost of HIV-related care in the HAART era at a university clinic in Sweden [abstract P19.10/01]. 11th European AIDS Conference; 2007 Oct 2427; Madrid, SpainGoogle Scholar
  15. 15.
    Caeckelbergh K, Moeremans K, Annemans L, et al. Cost of care for HIV/AIDS in Belgium according to disease stage [abstract P19.5/01]. 11th European AIDS Conference; 2007 Oct 2427; Madrid, SpainGoogle Scholar
  16. 16.
    Flori YA, le Vaillant M. Use and cost of antiretrovirals in France 19952000: an analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database. PharmacoEconomics 2004; 22: 1061–70PubMedCrossRefGoogle Scholar
  17. 17.
    Hicks C, Cahn P, Cooper DA, et al. Durable efficacy of tipranavirritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised openlabel trials. Lancet 2006; 368: 466–75PubMedCrossRefGoogle Scholar
  18. 18.
    Food and Drug Administration (FDA): Press Release: FDA approves darunavir; 2006 Jun 23 [online]. Available from URL: ( [Accessed 2010 Aug 25]Google Scholar
  19. 19.
    European Commission Community register of medicinal products for human use. PREZISTA; [online]. Available from URL: ( [Accessed 2010 Aug 25]
  20. 20.
    Clotet B, Bellos N, Molina J, et al. Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169–78PubMedCrossRefGoogle Scholar
  21. 21.
    Food and Drug Administration (FDA) Press Release. FDA approves novel antiretroviral drug; 2007 Aug 6 [online]. Available from URL: ( Scholar
  22. 22.
    Food and Drug Administration (FDA) Press Release. FDA approves new antiretroviral drug; 2007 Oct 16 [online]. Available from URL: ( [Accessed 2010 Aug 25]Google Scholar
  23. 23.
    Committee for Medicinal Products for Human Use (CHMP); 2007 [online]. Available from URL: ( [Accessed 2010 Aug 25]
  24. 24.
    Madruga JV, Cahn P, Grinsztejn B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29–38PubMedCrossRefGoogle Scholar
  25. 25.
    Lazzarin A, Campbell T, Clotet B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39–48PubMedCrossRefGoogle Scholar
  26. 26.
    GERS: Groupement pour l’Élaboration et la Réalisation de Statistiques. Nos missions; [online]. Available from URL: ( [Accessed 2010 Aug 25]
  27. 27.
    Banque Claude Bernard Data base Groupe CEGEDIM, Boulogne Billancourt France; [online]. Available from URL: ( [Accessed 2010 Aug 25]
  28. 28.
    Base de données Hospitalière Française sur l’infection à VIH — ANRS CO4 FHDH. Inserm transfert SA, Paris, France, 2007Google Scholar
  29. 29.
    ATIH: Agence Technique de l’information sur l’Hospitalisation. PSMI database; [online]. Available from URL: ( [Accessed 2010 Aug 25]
  30. 30.
    World Health Organization. International Classification of Diseases (ICD); [online]. Available from URL: ( [Accessed 2010 Aug 25]
  31. 31.
    Circulaire DHOS/F3/F1 no 2005-103 du 23 février 2005 relative àla campagne tarifaire 2005 pour les activités de médecine, chirurgie, obstétrique et odontologie exercé es dans les établissements de santéprivés mentionnés aux d) et e) de l’article L. 162-22-6 du code de la sécuritésociale; [online]. Available from URL: ( [Accessed 2010 Aug 25]
  32. 32.
    Vallier N, Weill A, Salanave B, et al. Coût des trente affections de longue duré e pour les béné ficiaires du ré gime gé né ral de l’assurance maladie en 2004. Prat Organ Soins 2006; 37: 267–83Google Scholar
  33. 33.
    Detournay B, Voinet C, Bez J, et al. Consommation médicale des patients infectés par le VIH suivis à l’Hôpital Purpan (Toulouse). Journal d’Economie Médicale 2003; 21: 367–76Google Scholar
  34. 34.
    Weill A, Chinaud F, Vallier N, et al. Fréquence et coûts des trente affections de longue durée de la région Midi-Pyrénées, anné e 2003. Rev Med Ass Maladie 2005; 36: 273–87Google Scholar
  35. 35.
    Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51–62PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Xavier Colin
    • 1
    Email author
  • Antoine Lafuma
    • 1
  • Dominique Costagliola
    • 2
  • Jean-Marie Lang
    • 3
  • Pascal Guillon
    • 4
  1. 1.CemkaBourg-la-ReineFrance
  2. 2.INSERM, Mixed Research Unit (UMR) S 720, and Universiteé Pierre et Marie Curie-Paris 6, UMR S 720ParisFrance
  3. 3.Clinique Medicale AStrasbourg University HospitalStrasbourgFrance
  4. 4.Janssen-Cilag SAS, Issy les MoulineauxFrance

Personalised recommendations